{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(7)"],"submitter":["Walmsley SL"],"pubmed_abstract":["Background
Females and persons of Black race are often underrepresented in clinical trials. This post hoc analysis of data from three phase 3 studies evaluated the efficacy and safety of doravirine (DOR) by sex and race in adults living with HIV-1.Methods
DRIVE-FORWARD and DRIVE-AHEAD open-label extensions were pooled; participants randomized to first-line DOR-based regimen continued from week (W) 96 to W192 (DOR-continued group) and participants randomized to comparators switched to DOR from W96 to W192 (DOR-switch group). In DRIVE-SHIFT, virologically suppressed adults were randomized to switch to a DOR-based regimen on day 1 (immediate-switch group) or W24 (delayed-switch group) and continued through W144. Results are reported by sex assigned at birth (male vs female) an"],"journal":["Open forum infectious diseases"],"pagination":["ofaf356"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12264332"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials."],"pmcid":["PMC12264332"],"pubmed_authors":["Kumar PN","Thompson M","Whiteside Y","Orkin C","Squires K","Walmsley SL","Plank RM","Lahoulou R","Xu ZJ","Greaves W"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials.","description":"Background
Females and persons of Black race are often underrepresented in clinical trials. This post hoc analysis of data from three phase 3 studies evaluated the efficacy and safety of doravirine (DOR) by sex and race in adults living with HIV-1.Methods
DRIVE-FORWARD and DRIVE-AHEAD open-label extensions were pooled; participants randomized to first-line DOR-based regimen continued from week (W) 96 to W192 (DOR-continued group) and participants randomized to comparators switched to DOR from W96 to W192 (DOR-switch group). In DRIVE-SHIFT, virologically suppressed adults were randomized to switch to a DOR-based regimen on day 1 (immediate-switch group) or W24 (delayed-switch group) and continued through W144. Results are reported by sex assigned at birth (male vs female) an","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-07-15T12:10:47.217Z","creation":"2025-08-14T03:05:22.758Z"},"accession":"S-EPMC12264332","cross_references":{"pubmed":["40672760"],"doi":["10.1093/ofid/ofaf356"]}}